US Patent Issued to Hoffmann-La Roche on May 19 for "Prevention or mitigation of T-cell engaging agent-related adverse effects" (Swiss, French, German Inventors)

ALEXANDRIA, Va., May 19 -- United States Patent no. 12,629,419, issued on May 19, was assigned to Hoffmann-La Roche Inc. (Little Falls, N.J.).

"Prevention or mitigation of T-cell engaging agent-related adverse effects" was invented by Helene Cecile Haegel (Illkirch-Graffenstaden, France), Christian Klein (Weilheim, Germany), Gabrielle Leclercq (Zurich), Alberto Toso (Basel, Switzerland) and Tina Zimmermann (Zurich).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to the prevention or mitigation of adverse effects related to T cell engaging agents, such as cytokine release syndrome. Specifically, the invention relates to the prevention or mitigation of such side effects using an inh...